NEW YORK (GenomeWeb News) – Link Technologies has licensed diagnostic reagent-related technology from the University of Manchester that it intends to market worldwide, the Scottish company said today.

Under the agreement with the University of Manchester Intellectual Property Limited, the firm acquired the rights to make and sell oligonucleotide reagents using the university's exciplex technology. It also will collaborate with the university to further develop the existing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.